Jewish Mutations in Prostate Cancer Patients
Author Information
Author(s): Vazina A, Baniel J, Yaacobi Y, Shtriker A, Engelstein D, Leibovitz I, Zehavi M, Sidi A A, Ramon Y, Tischler T, Livne P M, Friedman E
Primary Institution: Institute of Urology Rabin Medical Center, (Belinson Campus), Petach Tikvah
Hypothesis
Do BRCA1 and BRCA2 mutations contribute to prostate cancer in Jewish Israeli patients?
Conclusion
The rate of Jewish BRCA1 and BRCA2 mutations in prostate cancer patients is similar to that of the general population, indicating they contribute little to prostate cancer occurrence.
Supporting Evidence
- Inherited predisposition occurs in 5-10% of all prostate cancer patients.
- Germline mutations in BRCA1 and BRCA2 might be associated with an increased risk for prostate cancer.
- Five mutation carriers were detected among the study participants.
Takeaway
This study looked at prostate cancer patients to see if certain gene mutations were common. They found that these mutations are not more common in Jewish patients than in others.
Methodology
The study tested 174 unselected prostate cancer patients for BRCA1 and BRCA2 mutations using PCR amplification and modified restriction enzyme digests.
Limitations
The study only included unselected prostate cancer patients and may not represent all demographics.
Participant Demographics
Patients aged 45-81 years, with 95 of Ashkenazi origin.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website